TheRubins.com

Vaccinations and the Elderly- Part II of a II Part Series

Looking for regular updates as to where influenza is circulating including the latest information on the swine flu? Check www.cdc.gov/flu/weekly

Another good source to keep you updated on how the flu season is spreading in the United States and the world is at:  https://www.google.org/flutrends/us

(4/30/19)- Synopsis:

Influenza activity continues to decrease in the United States. Influenza A(H1N1)pdm09 viruses predominated from October to mid-February, and influenza A(H3N2) viruses have been more commonly identified since late February. Small numbers of influenza B viruses also have been reported. Below is a summary of the key influenza indicators for the week ending April 20, 2019:
The percentage of respiratory specimens testing positive for influenza viruses in clinical laboratories decreased. During the most recent three weeks, influenza A(H3) viruses were reported more frequently than influenza A(H1N1)pdm09 viruses nationally, and in all 10 HHS Regions.
:The majority of influenza A(H1N1)pdm09 and influenza B viruses characterized antigenically are similar to the cell-grown reference viruses representing the 2018–2019 Northern Hemisphere influenza vaccine viruses. However, the majority of influenza A(H3N2) viruses are antigenically distinguishable from A/Singapore/INFIMH-16-0019/2016 (3C.2a1), a cell-propagated reference virus representing the A(H3N2) component of 2018-19 Northern Hemisphere influenza vaccines.
The vast majority of influenza viruses tested (>99%) show susceptibility to oseltamivir and peramivir. All influenza viruses tested showed susceptibility to zanamivir.
The proportion of outpatient visits for influenza-like illness (ILI) decreased to 2.1%, which is below the national baseline of 2.2%. This is the first week ILI activity was below the national baseline since mid-November 2018. Four of 10 regions reported ILI at or above their region-specific baseline level
Puerto Rico experienced high ILI activity; one state experienced moderate ILI activity; nine states experienced low ILI activity; New York City, the District of Columbia and 40 states experienced minimal ILI activity; and the U.S. Virgin Islands had insufficient data
 The geographic spread of influenza in five states was reported as widespread; Puerto Rico and 17 states reported regional activity; 19 states reported local activity; the District of Columbia, the U.S. Virgin Islands and nine states reported sporadic activity; and Guam did not report.

 

(4/14/19)- 2018-2019 Influenza Season Week 14 ending April 6, 2019

 

All data are preliminary and may change as more reports are received.

An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available at http://www.cdc.gov/flu/weekly/overview.htm.

Synopsis:

Influenza activity continues to decrease but remains elevated in the United States. Influenza A(H1N1)pdm09 viruses predominated from October to mid-February, and influenza A(H3N2) viruses have been more commonly identified since late February. Small numbers of influenza B viruses have also been reported. Below is a summary of the key influenza indicators for the week ending April 6, 2019:

The percentage of respiratory specimens testing positive for influenza viruses in clinical laboratories decreased. Nationally, during the most recent three weeks, influenza A(H3) viruses were reported more frequently than influenza A(H1N1)pdm09 viruses and in all 10 HHS Regions.
The majority of influenza viruses characterized antigenically are similar to the cell-grown reference viruses representing the 2018–2019 Northern Hemisphere influenza vaccine viruses. However, an increasing proportion of influenza A(H3N2) viruses are antigenically distinguishable from  A/Singapore/INFIMH-16-0019/2016 (3C.2a1), a cell-propagated reference virus representing the A(H3N2) component of  2018-19 Northern Hemisphere influenza vaccines.
The vast majority of influenza viruses tested (>99%) show susceptibility to oseltamivir and peramivir. All influenza viruses tested showed susceptibility to zanamivir.
The proportion of outpatient visits for influenza-like illness (ILI) decreased to 2.8%, and remains above the national baseline of 2.2%. Nine of 10 regions reported ILI at or above their region-specific baseline level.
 Four states experienced high ILI activity; eight states experienced moderate ILI activity; New York City and 21 states experienced low ILI activity; the District of Columbia, Puerto Rico and 17 states experienced minimal ILI activity; and the U.S. Virgin Islands had insufficient data.
The geographic spread of influenza in 20 states was reported as widespread; Puerto Rico and 25 states reported regional activity; the District of Columbia and five states reported local activity; the U.S. Virgin Islands reported sporadic activity; Guam did not report.
A cumulative rate of 59.9 laboratory-confirmed influenza-associated hospitalizations per 100,000 population was reported. The highest hospitalization rate is among adults 65 years and older (195.9 hospitalizations per 100,000 population).
The proportion of deaths attributed to pneumonia and influenza (P&I) was below the system-specific epidemic threshold in the National Center for Health Statistics (NCHS) Mortality Surveillance System.Four influenza-associated pediatric deaths were reported to CDC during week 14

 

(4/7/19)- 2018-2019 Influenza Season Week 13 ending March 30, 2019

 

All data are preliminary and may change as more reports are received.

An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available at http://www.cdc.gov/flu/weekly/overview.htm.

Synopsis:

Influenza activity decreased but remains elevated in the United States. Influenza A(H1N1)pdm09 viruses predominated from October to mid-February, and influenza A(H3N2) viruses have been more commonly identified since late February. Small numbers of influenza B viruses have also been reported. Below is a summary of the key influenza indicators for the week ending March 30, 2019 The percentage of respiratory specimens testing positive for influenza viruses in clinical laboratories decreased. Nationally, during the most recent three weeks, influenza A(H3) viruses were reported more frequently than influenza A(H1N1)pdm09 viruses and in all 10 HHS Regions.

The majority of influenza viruses characterized antigenically are similar to the cell-grown reference viruses representing the 2018–2019 Northern Hemisphere influenza vaccine viruses. However, an increasing proportion of influenza A(H3N2) viruses are antigenically distinguishable from A/Singapore/INFIMH-16-0019/2016 (3C.2a1), a cell-propagated reference virus representing the A(H3N2) component of 2018-19 Northern Hemisphere influenza vaccines.
The vast majority of influenza viruses tested (>99%) show susceptibility to oseltamivir and peramivir. All influenza viruses tested showed susceptibility to zanamivir.
:The proportion of outpatient visits for influenza-like illness (ILI) decreased to 3.2%, and remains above the national baseline of 2.2%. All 10 regions reported ILI at or above their region-specific baseline level.
: Six states experienced high ILI activity; 19 states experienced moderate ILI activity; New York City, the District of Columbia, Puerto Rico and 13 states experienced low ILI activity; 12 states experienced minimal ILI activity; and the U.S. Virgin Islands had insufficient data.
 The geographic spread of influenza in Puerto Rico and 33 states was reported as widespread; 15 states reported regional activity; the District of Columbia and one state reported local activity; the U.S. Virgin Islands and Guam did not report.
A cumulative rate of 56.4 laboratory-confirmed influenza-associated hospitalizations per 100,000 population was reported. The highest hospitalization rate is among adults 65 years and older (181.8 hospitalizations per 100,000 population).
The proportion of deaths attributed to pneumonia and influenza (P&I) was at the system-specific epidemic threshold in the National Center for Health Statistics (NCHS) Mortality Surveillance System.
 Six influenza-associated pediatric deaths were reported to CDC during week 13. Five deaths occurred during the 2018-2019 season and one death occurred during the 2017-2018 season

 

(3/26/19)- The spread of a second strain of the flu virus, H3N2, since early February has caused this flu season to be longer than normal. This was the predominant flu strain last year, as opposed to the H1N1 strain earlier in the season.

The percentage of doctor visits for flu like symptoms last week, 4.4% is the highest figure for this time of the year since 1998, the first season the CDC began tracking flu prevalence this way.

(3/12/19) -2018-2019 Influenza Season Week 9 ending March 2, 2019

 

All data are preliminary and may change as more reports are received.

An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available at http://www.cdc.gov/flu/weekly/overview.htm.

Synopsis:

Influenza activity remains elevated in the United States. Influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B viruses continue to co-circulate. Below is a summary of the key influenza indicators for the week ending March 2, 2019:

The percentage of respiratory specimens testing positive for influenza viruses in clinical laboratories increased slightly. Nationally, during week 9, influenza A(H3) viruses were reported more frequently than influenza A(H1N1)pdm09 viruses. During the most recent three weeks, influenza A(H3) viruses were reported more frequently than influenza A(H1N1)pdm09 viruses in HHS Regions 2, 4, 6, 7 and 8.

Virus Characterization:The majority of influenza viruses characterized antigenically are similar to the cell-grown reference viruses representing the 2018–2019 Northern Hemisphere influenza vaccine viruses.

Antiviral Resistance:TThe vast majority of influenza viruses tested (>99%) show susceptibility to oseltamivir and peramivir. All influenza viruses tested showed susceptibility to zanamivir.

The proportion of outpatient visits for influenza-like illness (ILI) decreased slightly to 4.7%, which is above the national baseline of 2.2%. All 10 regions reported ILI at or above their region-specific baseline level.

ILI State Activity Indictor Map: 32 states experienced high ILI activity; Puerto Rico and seven states experienced moderate ILI activity; New York City, the District of Columbia and eight states experienced low ILI activity; three states experienced minimal ILI activity; and the U.S. Virgin Islands had insufficient data. The geographic spread of influenza in Puerto Rico and 48 states was reported as widespread; the District of Columbia and two states reported local activity; the U.S. Virgin Islands reported sporadic activity; and Guam did not report.

A cumulative rate of 36.6 laboratory-confirmed influenza-associated hospitalizations per 100,000 population was reported. The highest hospitalization rate is among adults 65 years and older (107.7 hospitalizations per 100,000 population).

The proportion of deaths attributed to pneumonia and influenza (P&I) was above the system-specific epidemic threshold in the National Center for Health Statistics (NCHS) Mortality Surveillance System.

 Nine influenza-associated pediatric deaths were reported to CDC during week 9. Eight deaths occurred during the 2018-2019 season and one death occurred during the 2015-2016 season.

 

(3/5/19)- -2019 Influenza Season Week 8 ending February 23, 2019

 

All data are preliminary and may change as more reports are received.

An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available at http://www.cdc.gov/flu/weekly/overview.htm.

Synopsis:

Influenza activity remains elevated in the United States. Influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B viruses continue to co-circulate. Below is a summary of the key influenza indicators for the week ending February 23, 2019:
 The percentage of respiratory specimens testing positive for influenza viruses in clinical laboratories increased slightly. Nationally, during week 8, influenza A(H3) viruses were reported more frequently than influenza A(H1N1)pdm09 viruses. During the most recent three weeks, influenza A(H3) viruses were reported more frequently than influenza A(H1N1)pdm09 viruses in HHS Regions 2, 4, 6 and 7.

 The majority of influenza viruses characterized antigenically are similar to the cell-grown reference viruses representing the 2018–2019 Northern Hemisphere influenza vaccine viruses.

 :The vast majority of influenza viruses tested (>99%) show susceptibility to oseltamivir and peramivir. All influenza viruses tested showed susceptibility to zanamivir.

The proportion of outpatient visits for influenza-like illness (ILI) remained at 5.0%, which is above the national baseline of 2.2%. All 10 regions reported ILI at or above their region-specific baseline level.

 New York City and 33 states experienced high ILI activity; the District of Columbia and eight states experienced moderate ILI activity; Puerto Rico and eight states experienced low ILI activity; one state experienced minimal ILI activity; and the U.S. Virgin Islands had insufficient data.
 The geographic spread of influenza in Puerto Rico and 49 states was reported as widespread; the District of Columbia and one state reported local activity; the U.S. Virgin Islands reported sporadic activity; and Guam did not report.

A cumulative rate of 32.1 laboratory-confirmed influenza-associated hospitalizations per 100,000 population was reported. The highest hospitalization rate is among adults 65 years and older (91.5 hospitalizations per 100,000 population).

 The proportion of deaths attributed to pneumonia and influenza (P&I) was below the system-specific epidemic threshold in the National Center for Health Statistics (NCHS) Mortality Surveillance System.

15 influenza-associated pediatric deaths were reported to CDC during week 8.

 

(2/26/19)- 2018-2019 Influenza Season Week 7 ending February 16, 2019

 

All data are preliminary and may change as more reports are received.

An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available at http://www.cdc.gov/flu/weekly/overview.htm.

Synopsis:

Influenza activity continues to increase in the United States. Influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B viruses continue to co-circulate. Below is a summary of the key influenza indicators for the week ending February 16, 2019:

o    Viral Surveillance:The percentage of respiratory specimens testing positive for influenza viruses in clinical laboratories increased. While influenza A(H1N1)pdm09 viruses predominated in most areas of the country, influenza A(H3) viruses have predominated in HHS Region 4 and accounted for 47% of subtyped influenza A viruses detected nationally during week 7. During the most recent three weeks, influenza A(H3) viruses were reported more frequently than influenza A(H1N1)pdm09 viruses in HHS Regions 6 and 7 and influenza A(H1N1)pdm09 and influenza A(H3) viruses were reported in approximately equal numbers in HHS Region 2.

o    Virus Characterization:The majority of influenza viruses characterized antigenically are similar to the cell-grown reference viruses representing the 2018–2019 Northern Hemisphere influenza vaccine viruses.

o    Antiviral Resistance:The vast majority of influenza viruses tested (>99%) show susceptibility to oseltamivir and peramivir. All influenza viruses tested showed susceptibility to zanamivir.The proportion of outpatient visits for influenza-like illness (ILI) increased to 5.1%, which is above the national baseline of 2.2%. All 10 regions reported ILI at or above their region-specific baseline level.

o    ILI State Activity Indictor Map: New York City and 30 states experienced high ILI activity; the District of Columbia and 11 states experienced moderate ILI activity; six states experienced low ILI activity; the U.S. Virgin Islands and three states experienced minimal ILI activity; and Puerto Rico had insufficient data. The geographic spread of influenza in Puerto Rico and 48 states was reported as widespread; one state reported regional activity; the District of Columbia reported local activity; the U.S. Virgin Islands and one state reported sporadic activity; and Guam did not report.            

o    A cumulative rate of 27.4 laboratory-confirmed influenza-associated hospitalizations per 100,000 population was reported. The highest hospitalization rate is among adults 65 years and older (75.6 hospitalizations per 100,000 population).

o    The proportion of deaths attributed to pneumonia and influenza (P&I) was below the system-specific epidemic threshold in the National Center for Health Statistics (NCHS) Mortality Surveillance System.

o     Seven influenza-associated pediatric deaths were reported to CDC during week 7.

 

(2/17/19)- The Centers for Disease Control and Prevention (CDC) estimates as many as15.2 million people have had the flu this season in this country, through February 2. Thev vaccine used this year reduced the chance of visiting doctors this season for the ailment by 47% compared to the 40% for last year’s flu season. The CDC estimates that as many as 186,000 were hospitalized with the disease from the beginning of October through February 2., while as many as15,000 died from it

(2/14/19)  A new pill that can kill the flu virus within 24 hours, which was approved by regulators in both Japan and the U.S, last year has come under question by some leading medical experts in this country.

The pill, called Xofluza, was developed by Osaka based Shionogi & Co. and is marketed in the U. S. by Roche Holding Co.’s Genentech unit. The pill is taken once unlike Roche’s Tamiflu which is taken twice a day for 5 days. The drug’s list price is $150.

 2/10/19)- 2018-2019 Influenza Season Week 5 ending February 2, 2019

All data are preliminary and may change as more reports are received.

An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available at http://www.cdc.gov/flu/weekly/overview.htm.

Synopsis:

Influenza activity increased in the United States. Influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B viruses continue to co-circulate. Below is a summary of the key influenza indicators for the week ending February 2, 2019

The percentage of respiratory specimens testing positive for influenza viruses in clinical laboratories increased. Influenza A viruses have predominated in the United States since the beginning of October. Influenza A(H1N1)pdm09 viruses have predominated in most areas of the country, however influenza A(H3) viruses have predominated in the southeastern United States (HHS Region 4).

The majority of influenza viruses characterized antigenically and genetically are similar to the cell-grown reference viruses representing the 2018–2019 Northern Hemisphere influenza vaccine viruses.

The vast majority of influenza viruses tested (>99%) show susceptibility to oseltamivir and peramivir. All influenza viruses tested showed susceptibility to zanamivir. The proportion of outpatient visits for influenza-like illness (ILI) increased to 4.3%, which is above the national baseline of 2.2%. All 10 regions reported ILI at or above their region-specific baseline level.

 New York City and 24 states experienced high ILI activity; Puerto Rico and 10 states experienced moderate ILI activity; the District of Columbia and 13 states experienced low ILI activity; and three states experienced minimal ILI activity.

 The geographic spread of influenza in Puerto Rico and 47 states was reported as widespread; two states reported regional activity; the District of Columbia and one state reported local activity; the U.S. Virgin Islands reported sporadic activity; and Guam did not report.

A cumulative rate of 20.1 laboratory-confirmed influenza-associated hospitalizations per 100,000 population was reported. The highest hospitalization rate is among adults 65 years and older (53.0 hospitalizations per 100,000 population).

The proportion of deaths attributed to pneumonia and influenza (P&I) was below the system-specific epidemic threshold in the National Center for Health Statistics (NCHS) Mortality Surveillance System. Four influenza-associated pediatric deaths were reported to CDC during week 5.

 

(2/4/19)- 2018-2019 Influenza Season Week 4 ending January 26, 2019

 

All data are preliminary and may change as more reports are received.

An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available at http://www.cdc.gov/flu/weekly/overview.htm.

Synopsis:

Influenza activity increased in the United States. Influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B viruses continue to co-circulate. Below is a summary of the key influenza indicators for the week ending January 26, 2019: The percentage of respiratory specimens testing positive for influenza viruses in clinical laboratories increased. Influenza A viruses have predominated in the United States since the beginning of October. Influenza A(H1N1)pdm09 viruses have predominated in most areas of the country, however influenza A(H3) viruses have predominated in the southeastern United States (HHS Region 4).

The majority of influenza viruses characterized antigenically and genetically are similar to the cell-grown reference viruses representing the 2018–2019 Northern Hemisphere influenza vaccine viruses.

The vast majority of influenza viruses tested (>99%) show susceptibility to oseltamivir and peramivir. All influenza viruses tested showed susceptibility to zanamivir. The proportion of outpatient visits for influenza-like illness (ILI) increased to 3.8%, which is above the national baseline of 2.2%. All 10 regions reported ILI at or above their region-specific baseline level.

New York City and 23 states experienced high ILI activity; Puerto Rico and 10 states experienced moderate ILI activity; the District of Columbia and 13 states experienced low ILI activity; and four states experienced minimal ILI activity. The geographic spread of influenza in 45 states was reported as widespread; Puerto Rico and three states reported regional activity; two states reported local activity; the District of Columbia and the U.S. Virgin Islands reported sporadic activity; and Guam did not report.

A cumulative rate of 15.3 laboratory-confirmed influenza-associated hospitalizations per 100,000 population was reported. The highest hospitalization rate is among adults 65 years and older (39.8 hospitalizations per 100,000 population).

The proportion of deaths attributed to pneumonia and influenza (P&I) was at the system-specific epidemic threshold in the National Center for Health Statistics (NCHS) Mortality Surveillance System.

(1/27/19)- 2018-2019 Influenza Season Week 3 ending January 19, 2019

 

All data are preliminary and may change as more reports are received.

An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available at http://www.cdc.gov/flu/weekly/overview.htm.

Synopsis:

Influenza activity increased in the United States. Influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B viruses continue to co-circulate. Below is a summary of the key influenza indicators for the week ending January 19, 2019:

The percentage of respiratory specimens testing positive for influenza viruses in clinical laboratories increased. Influenza A viruses have predominated in the United States since the beginning of October. Influenza A(H1N1)pdm09 viruses have predominated in most areas of the country, however influenza A(H3) viruses have predominated in the southeastern United States (HHS Region 4)
The majority of influenza viruses characterized antigenically and genetically are similar to the cell-grown reference viruses representing the 2018–2019 Northern Hemisphere influenza vaccine viruses.
The vast majority of influenza viruses tested (>99%) show susceptibility to oseltamivir and peramivir. All influenza viruses tested showed susceptibility to zanamivir.
The proportion of outpatient visits for influenza-like illness (ILI) increased to 3.3%, which is above the national baseline of 2.2%. All 10 regions reported ILI at or above their region-specific baseline level.
New York City and 18 states experienced high ILI activity; 10 states experienced moderate ILI activity; the District of Columbia and eight states experienced low ILI activity; 14 states experienced minimal ILI activity; and Puerto Rico had insufficient data.
The geographic spread of influenza in 36 states was reported as widespread; Puerto Rico and 11 states reported regional activity; three states reported local activity; the District of Columbia and the U.S. Virgin Islands reported sporadic activity; and Guam did not report.
A cumulative rate of 14.8 laboratory-confirmed influenza-associated hospitalizations per 100,000 population was reported.  The highest hospitalization rate is among adults 65 years and older (38.3 hospitalizations per 100,000 population
The proportion of deaths attributed to pneumonia and influenza (P&I) was above the system-specific epidemic threshold in the National Center for Health Statistics (NCHS) Mortality Surveillance System.
Three influenza-associated pediatric deaths were reported to CDC during week 3.

 

(1/21/19)- 2018-2019 Influenza Season Week 2 ending January 12, 2019

 

All data are preliminary and may change as more reports are received.

An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available at http://www.cdc.gov/flu/weekly/overview.htm.

Synopsis:

Influenza activity remains elevated in the United States. Influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B viruses continue to co-circulate. Below is a summary of the key influenza indicators for the week ending January 12, 2019:

The percentage of respiratory specimens testing positive for influenza viruses in clinical laboratories decreased slightly. Influenza A viruses have predominated in the United States since the beginning of October. Influenza A(H1N1)pdm09 viruses have predominated in most areas of the country, however influenza A(H3) viruses have predominated in the southeastern United States (HHS Region 4).

Virus Characterization: The majority of influenza viruses characterized antigenically and genetically are similar to the cell-grown reference viruses representing the 2018–2019 Northern Hemisphere influenza vaccine viruses.

Antiviral Resistance: None of the viruses tested were associated with highly reduced inhibition by any of the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir).

Influenza-like Illness Surveillance:The proportion of outpatient visits for influenza-like illness (ILI) decreased from 3.5% to 3.1%, but remains above the national baseline of 2.2%. All 10 regions reported ILI at or above their region-specific baseline level.

ILI State Activity Indictor Map: Nine states experienced high ILI activity; New York City and 13 states experienced moderate ILI activity; 10 states experienced low ILI activity; and the District of Columbia, Puerto Rico and 18 states experienced minimal ILI activity.

Geographic Spread of Influenza: The geographic spread of influenza in Guam and 30 states was reported as widespread; Puerto Rico and 16 states reported regional activity; three states reported local activity; and the District of Columbia, the U.S. Virgin Islands and one state reported sporadic activity.

Influenza-associated Hospitalizations A cumulative rate of 12.4 laboratory-confirmed influenza-associated hospitalizations per 100,000 population was reported. The highest hospitalization rate is among adults 65 years and older (31.9 hospitalizations per 100,000 population).

Pneumonia and Influenza Mortality: The proportion of deaths attributed to pneumonia and influenza (P&I) was below the system-specific epidemic threshold in the National Center for Health Statistics (NCHS) Mortality Surveillance System.

Influenza-associated Pediatric Deaths: Three influenza-associated pediatric deaths were reported to CDC during week 2.

 

(1/14/19)- The current flu season appears less severe than the flu-season of 2017-18, and the vaccine being used seems to be effective in fighting both the H1N1 and H3N2 variations of the present virus, according to the Center for Disease Control and Prevention. About 69,3000 to 83,500 have been hospitalized with the disease so far this year, as opposed to the 959,000 hospitalized last year.

2018-2019 Influenza Season Week 1 ending January 5, 2019

 

All data are preliminary and may change as more reports are received.

An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available at http://www.cdc.gov/flu/weekly/overview.htm.,

Synopsis:

Influenza activity remains elevated in the United States. Influenza A(H1N1)pdm09, influenza A(H3N2), and influenza B viruses continue to co-circulate. Below is a summary of the key influenza indicators for the week ending January 5, 2019:

The percentage of respiratory specimens testing positive for influenza viruses in clinical laboratories decreased slightly. Influenza A viruses have predominated in the United States since the beginning of October. Influenza A(H1N1)pdm09 viruses have predominated in most areas of the country, however influenza A(H3) viruses have predominated in the southeastern United States (HHS Region 4).

 The majority of influenza viruses characterized antigenically and genetically are similar to the cell-grown reference viruses representing the 2018–2019 Northern Hemisphere influenza vaccine viruses.

 All viruses tested show susceptibility to the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir).

The proportion of outpatient visits for influenza-like illness (ILI) decreased from 4.0% to 3.5%, but remains above the national baseline of 2.2%. All 10 regions reported ILI at or above their region-specific baseline level.

New York City and 15 states experienced high ILI activity; 12 states experienced moderate ILI activity; the District of Columbia, Puerto Rico and eight states experienced low ILI activity; and 15 states experienced minimal ILI activity.

The geographic spread of influenza in 30 states was reported as widespread; Puerto Rico and 17 states reported regional activity; two states reported local activity; the District of Columbia, the U.S. Virgin Islands and one state reported sporadic activity; and Guam did not report.

A cumulative rate of 9.1 laboratory-confirmed influenza-associated hospitalizations per 100,000 population was reported. The highest hospitalization rate is among adults 65 years and older (22.9 hospitalizations per 100,000 population).
The proportion of deaths attributed to pneumonia and influenza (P&I) was below the system-specific epidemic threshold in the National Center for Health Statistics (NCHS) Mortality Surveillance System.

Three influenza-associated pediatric deaths were reported to CDC during week 1.

 

(1/7/19)- 2018-2019 Influenza Season Week 52 ending December 29, 2018- Influenza activity in the United States is increasing. Influenza A(H1N1), influenza A(H3N2), and influenza B viruses continue to co-circulate.

(12/31/18)- 2018-2019 Influenza Season Week 51 ending December 22, 2018 Influenza activity in the United States is increasing. (5/1/18)- During week 16 (April 15-21, 2018), influenza activity decreased in the United States.
(4/16/18)- During week 14 (April 1-7, 2018), influenza activity decreased in the United States.(4/8/18)- During week 13 (March 25-31, 2018), influenza activity decreased in the United States.
(3/31/18- During week 12 (March 18-24, 2018), influenza activity decreased in the United States.
(3/26/18)- During week 11 (March 11-17, 2018), influenza activity decreased in the United States.
(3/18/18)- During week 10 (March 4-10, 2018), influenza activity decreased in the United States.
(3/12/18)-
During week 9 (February 25-March 3, 2018), influenza activity decreased in the United States.
(3/4/18)- During week 8 (February 18-24, 2018), influenza activity decreased in the United States.

 

(2/26/18)- Japan’s health ministry has granted fast-track approval to Shinnogi & Co.’s.flu-virus killing drug Xofluza for sale in that country. The pill can kill the virus in 24 hours, but it may not be available until May at the earliest, because the Japanese national insurer has not set a price for the drug.

A late stage trial showed Xofluza was faster at killing the flu virus than any other treatment including Roche AG’s Tamiflu.

During week 7 (February 11-17, 2018), influenza activity remained elevated in the United States.
(2/18/18)- During week 6 (February 4-10, 2018), influenza activity remained elevated in the United States.
(2/11/18)- During week 5 (January 28-February 3, 2018), influenza activity increased in the United States.
(2/6/18)- During week 4 (January 21-27, 2018), influenza activity increased in the United States.

(1/30/18)- Medical experts are advising people who have not received the flu shot to get it, even though it is late in the season. If your medical provider is out of the vaccine, you can go to www.vaccinefinder.org to find the nearest medical facility that has the vaccine available.

The 2017-2018 flu season is on track to match the 2014-2015 season when 34 million Americans got the flu, 710,00 were hospitalized by it and about 56.000 died from it.

(1/26/18)- During week 3 (January 14-20, 2018), influenza activity increased in the United States.

(1/24/18)- The Center for Disease Control and Prevention (CDC)- reported on Monday that the number of people sick with the flu is continuing to climb, and has not peaked yet, as it does in the “normal” flu season. This flu season is the most intense since the 2009-2010 pandemic.

The percentage of outpatient visits has now surpassed all preceding years back to the 2009-2010 flu season, when a new strain of the flu virus spread around the world.

Medical experts are now estimating that this year’s flu vaccine has been less than 30% effective.

(1/21/18)- This year’s flu season is very similar to the 2014-2015 flu season, with both being dominated by the H3N2 flu strain, and both being “moderately severe”. A little less than 6% of all Americans seeking medical care now have flu symptoms.

During week 2 (January 7-13, 2018), influenza activity increased in the United States.
(1/16/18)- During week 1 (December 31, 2017-January 6, 2018), influenza activity increased in the United States.
(1/7/18)- During week 52 (December 24-30, 2017), influenza activity increased sharply in the United States.
(12/31/17)- During week 51 (December 17-23, 2017), influenza activity increased sharply in the United States.
(12/26/17)-
During week 50 (December 10-16, 2017), influenza activity sharply increased in the United States
(12/18/17)- During week 49 (December 3-9, 2017), influenza activity increased in the United States.
(12/10/17)- During week 48 (November 26-December 2, 2017), overall influenza activity increased slightly in the United States
(11/23/17)- During week 45 (November 5-11, 2017), influenza activity is increasing in the United States.
(11/12/17)- During week 44 (October 29-November 4, 2017), influenza activity remained low in the United States, but is increasing.

(11/10/17)- Last year’s flu vaccine was only 20% to 30% effective in the U.S. because the predominant flu strain, H3N2, mutated upon contact with chicken eggs when grown in culture to make vaccines. If the predominant influenza strain this year is H1N1, the vaccine could be as much as 60% effective, but if it's H3N2, poor results may repeat

(11/6/17)-During week 43 (October 22-28, 2017), influenza activity was low in the United States.

FOR AN INFORMATIVE AND PERSONAL ARTICLE ON PRACTICAL SUGGESTIONS WHEN SELECTING A NURSING HOME SEE OUR ARTICLE "How to Select a Nursing Home"

Please see Vaccinations and the Elderly –Part I of this Series

By Allan Rubin
updated April 30, 2019

http://www.therubins.com

To e-mail: hrubin12@nyc.rr.com or allanrubin4@gmail.com

Return to Home

TheRubins.com